Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

24.83 +0.03 (+0.11%)
Streaming Delayed Price Updated: 12:43 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Forget Tech! 3 Value Stocks That Could Win Big From Rate Cuts.
Several value stocks are poised to benefit richly from upcoming rate cuts that could happen as soon as September when the Fed reconvenes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Dividend Growth Stocks to Buy Hand Over Fist in August
There are blue-chip bargains paying large and growing dividends in the healthcare space. 
Via The Motley Fool
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END 
Via FinancialNewsMedia
Is Pfizer Winning Its $43 Billion Bet?
Pfizer's efforts are starting to bear fruit. 
Via The Motley Fool
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
From FN Media Group LLC
Via GlobeNewswire
3 Cheap Stocks to Buy in August for Under $50
It is never too early or too late to start investing, so choose these cheap stocks under $50 to start building your portfolio. 
Via InvestorPlace
3 Unstoppable Dividend Stocks Yielding More Than 4% for Income-Seeking Investors to Buy in August and Hold Forever
The dividend payments you can receive from these high-yield stocks are yours to keep, regardless of a market correction. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Shares of the rare disease drugmaker are already up more than 40% over the past year. 
Via The Motley Fool
Volatility Spikes: 3 Low Beta Stocks To Buy
Over recent months, several low-beta stocks have enjoyed positive earnings estimate revisions. For those looking for a higher level of defense, let’s take a closer look at each. 
Via Talk Markets
Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage... 
Via Benzinga
Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
Moderna sustained a rare downgrade on Monday following its guidance cut for the year. 
Via Investor's Business Daily
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
BioNTech posted a significant Q2 2024 loss of 807.8 million euros. Sales dropped to 128.7 million euros as the demand for COVID-19 vaccines shifted. R&D expenses rose due to late-stage oncology... 
Via Benzinga
Exposures COVID-19
Investing $100,000 in These 7 High-Yield Dividend Stocks Could Generate Over $7,000 in Annual Passive Income
Making passive income should be easy with these great stocks. 
Via The Motley Fool
2 Ultra-High-Yield Dividend Stocks to Buy in August and Hold at Least a Decade
With an average yield above 7% at recent prices, these stocks could give your passive income stream a big boost. 
Via The Motley Fool
Is This Decision by Pfizer Bad News for Eli Lilly?
Lilly's revenue gains have helped its stock to roar higher. 
Via The Motley Fool
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from... 
Via Benzinga
Exposures COVID-19
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours. 
Via InvestorPlace
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Subdued Blue-Chip Stocks That Will Reward Patient Investors
These are the blue-chip stocks to buy as they represent companies with strong fundamentals and growth acceleration possibility. 
Via InvestorPlace
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment. 
Via InvestorPlace
Phio Pharmaceuticals Announces New Chief Financial Officer
Marlborough, Massachusetts--(Newsfile Corp. - August 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary... 
Via Newsfile
Topics Initial Public Offering
Exposures Securities Market
Moderna Slashes Its Outlook On 'Very Low' European Sales Despite Quarterly Beat
Moderna delivered nearly double the sales analysts expected in the second quarter. 
Via Investor's Business Daily
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
This big pharma stock gives investors juicy and reliable dividends plus the potential for future growth. 
Via The Motley Fool
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Pfizer shares have advanced 20% over the past three months. 
Via The Motley Fool
The Top 7 Stocks to Buy Now: Summer 2024
Investors should give consideration to taking a position in one of these top stocks to buy that are flashing strong growth signals. 
Via InvestorPlace
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
Pfizer reported second-quarter adjusted EPS of $0.60, surpassing the consensus of $0.46. Sales reached $13.28 billion, beating expectations. Analysts highlight Pfizer's robust portfolio, effective... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS